Application of a mixed type of optimization in the implementation of pharmaceutical development of a dosage form of eye drops based on oligohexamethyleneguanidine hydrosuccinate

Abstract

This study focused on the implementation of the stages of pharmaceutical development of a dosage form of eye drops based on the branched oligohexamethylene guanidine hydrosuccinate according to discrete and continuous optimization, followed by risk assessment and process validation. Experimental samples were developed, critical process and quality parameters were identified, technological characteristics were measured, parameters were normalized, a forecast was made, confirmatory experiments were conducted, the optimal composition was identified, risks in the production of eye drops were assessed, and partial validation was performed. During the implementation of the stages of pharmaceutical development of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, three optimization cycles (discrete and continuous) were carried out, and the optimal ratio of active and auxiliary components was justified based on the results (branched oligohexamethylene guanidine hydrosuccinate 0.05%, polyvinyl alcohol 1%, phosphate-buffered saline 20%, sodium chloride 0.45%, and purified water up to 100%). After reviewing the technological process considering risk analysis, critical points were identified, and partial validation was performed, and the positive results verified and confirmed the optimal choice at this stage of pharmaceutical development. In general, a mixed type of optimization (discrete and continuous) can be used to implement pharmaceutical developments of eye drops based on branched oligohexamethylene guanidine hydrosuccinate, which is confirmed by a series of experiments and risk assessment, and the partial validation verified the data obtained. Thus, pharmaceutical development is a complex and time-consuming process, and limited functionality does not always allow quick identification of the optimal composition of a drug. As an effective solution for implementing the stages of pharmaceutical development, mathematical modeling methods and various types of optimization can be applied.

Keywords

risk analysis / validation / eye drops / discrete optimization / math modeling / oligohexamethylene guanidine succinate / ophthalmology / pharmaceutical development

References

[1] Shilovskikh OV, Ponomarev VO, Kazaykin VN, et al. Bacterial keratitis. Part 1. Epidemiology, etiology, pathophysiology, risk factors, clinic, current aspects of diagnosis. Ophthalmology in Russia. 2023;20(1): 17–23. EDN: BSRWLW doi: 10.18008/1816-5095-2023-1-17-23

[2] Шиловских О.В., Пономарев В.О., Казайкин В.Н., и др. Бактериальный кератит. Часть 1. Эпидемиология, этиология, патофизиология, факторы риска, клиника, актуальные аспекты диагностики // Офтальмология. 2023. Т. 20, № 1. С. 17–23. EDN: BSRWLW doi: 10.18008/1816-5095-2023-1-17-23

[3] Shilovskikh OV, Ponomarev VO, Kazaykin VN, et al. Bacterial keratitis. Part 1. Epidemiology, etiology, pathophysiology, risk factors, clinic, current aspects of diagnosis. Ophthalmology in Russia. 2023;20(1): 17–23. EDN: BSRWLW doi: 10.18008/1816-5095-2023-1-17-23

[4] Brzheskiy VV. Modern opportunities for the prevention and treatment of inflammatory eye diseases of an infectious nature in children. Ophthalmology reports. 2019;12(4):57–65. EDN: JQDGEV doi: 10.17816/OVI8917

[5] Бржеский В.В. Современные возможности профилактики и лечения воспалительных заболеваний глаз инфекционной природы у детей // Офтальмологические ведомости. 2019. Т. 12, № 4. С. 57–65. EDN: JQDGEV doi: 10.17816/OVI8917

[6] Brzheskiy VV. Modern opportunities for the prevention and treatment of inflammatory eye diseases of an infectious nature in children. Ophthalmology reports. 2019;12(4):57–65. EDN: JQDGEV doi: 10.17816/OVI8917

[7] Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020;15(3):372–395. doi: 10.18502/jovr.v15i3.7456

[8] Azari A.A., Arabi A. Conjunctivitis: a systematic review // J Ophthalmic Vis Res. 2020. Vol. 15, N. 3. P. 372–395. doi: 10.18502/jovr.v15i3.7456

[9] Azari AA, Arabi A. Conjunctivitis: a systematic review. J Ophthalmic Vis Res. 2020;15(3):372–395. doi: 10.18502/jovr.v15i3.7456

[10] Babushkin AE. Local antibiotic therapy of bacterial infectious and inflammatory diseases of the anterior segment of the eye (literature review). Point of view. East-West. 2021. № 2. С. 89–93. EDN: JFYMGR doi: 10.25276/2410-1257-2021-2-89-93

[11] Бабушкин А.Э. Местная антибиотикотерапия бактериальных инфекционно-воспалительных заболеваний переднего отрезка глаза // Точка зрения. Восток-Запад. 2021. № 2. С. 89–93. EDN: JFYMGR doi: 10.25276/2410-1257-2021-2-89-93

[12] Babushkin AE. Local antibiotic therapy of bacterial infectious and inflammatory diseases of the anterior segment of the eye (literature review). Point of view. East-West. 2021. № 2. С. 89–93. EDN: JFYMGR doi: 10.25276/2410-1257-2021-2-89-93

[13] Ivanov IS, Shatalov DO, Kedik SA, et al. Study of the effect of the pharmaceutical substance branched oligohexamethylene guanidine hydrosuccinate in relation to microorganisms. Antibiotics and Chemotherapy. 2019;64(11-12):8–15. EDN: RRPUIR doi: 10.1016/0235-2990-2019-64-11-12-8-15

[14] Иванов И.С., Шаталов Д.О., Кедик С.А. Изучение действия фармацевтической субстанции гидросукцинат разветвленного олигогексаметиленгуанидина в отношении микроорганизмов // Антибиотики и Химиотерапия. 2019. Т. 64, № 11-12. С. 8–15. EDN: RRPUIR doi: 10.1016/0235-2990-2019-64-11-12-8-15

[15] Ivanov IS, Shatalov DO, Kedik SA, et al. Study of the effect of the pharmaceutical substance branched oligohexamethylene guanidine hydrosuccinate in relation to microorganisms. Antibiotics and Chemotherapy. 2019;64(11-12):8–15. EDN: RRPUIR doi: 10.1016/0235-2990-2019-64-11-12-8-15

[16] Kornyushko VF, Nikolaeva OM, Panov AV, et al. Quality management of the chemical-technological process for continuous synthesis of pharmaceutical substances of medicinal compounds in flow microreactors. Fine Chemical Technologies. 2021;16(3):252–266. EDN: GRYFHU doi: 10.32362/2410-6593-2021-16-3-252-266

[17] Корнюшко В.Ф., Николаева О.М., Панов А.В., и др. Управление качеством химико-технологического процесса непрерывного синтеза активной фармацевтической субстанции лекарственных соединений в проточных микрореакторах // Тонкие химические технологии. 2021. Т. 16, № 3. С. 252–266. EDN: GRYFHU doi: 10.32362/2410-6593-2021-16-3-252-266

[18] Kornyushko VF, Nikolaeva OM, Panov AV, et al. Quality management of the chemical-technological process for continuous synthesis of pharmaceutical substances of medicinal compounds in flow microreactors. Fine Chemical Technologies. 2021;16(3):252–266. EDN: GRYFHU doi: 10.32362/2410-6593-2021-16-3-252-266

[19] Ivanov IS. Microfluidic synthesis of hydrosuccinate-oligohexamethyleneguanidine substance and creation of ophthalmic preparation on its basis [dissertation]. Moscow; 2021. 118 p. (In Russ.).

[20] Иванов И.С. Микрофлюидный синтез субстанции гидросукцинатаолигогексаметиленгуанидина и создание офтальмологического препарата на ее основе: дис. ... канд. фарм. наук. Москва, 2021. 118 с.

[21] Ivanov IS. Microfluidic synthesis of hydrosuccinate-oligohexamethyleneguanidine substance and creation of ophthalmic preparation on its basis [dissertation]. Moscow; 2021. 118 p. (In Russ.).

[22] Shatalov DO. Development and standardization of quality control methods for branched oligohexamethyleneguanidine hydrochloride [dissertation]. Moscow; 2015. 137 p. (In Russ.).

[23] Шаталов Д.О. Разработка и стандартизация методов контроля качества разветвленного олигогексаметиленгуанидин гидрохлорида: дис. ... канд. фарм. наук. Москва, 2015. 137 с.

[24] Shatalov DO. Development and standardization of quality control methods for branched oligohexamethyleneguanidine hydrochloride [dissertation]. Moscow; 2015. 137 p. (In Russ.).

[25] McDermott RE, Mikulak RJ, Beauregard MR. The basics of FMEA. 2nd edit. New York: Productivity Press; 2009, 90 р.

[26] McDermott R.E., Mikulak R.J., Beauregard M.R. The basics of FMEA. 2nd edit. New York: Productivity Press, 2009, 90 р.

[27] McDermott RE, Mikulak RJ, Beauregard MR. The basics of FMEA. 2nd edit. New York: Productivity Press; 2009, 90 р.

RIGHTS & PERMISSIONS

Eco-Vector